TXI is dedicated to overcoming the obstacles that hinder scientists from accessing and leveraging data effectively. In biopharma, vast amounts of data are often siloed and compartmentalized, making it challenging to integrate with external data, such as real-world data (RWD), or even across internal data sets. This fragmentation poses a significant obstacle to accelerating the development of novel treatments, perpetuating the industry's current norm of taking ten years and costing over $2 billion.
To unleash the potential of data in biopharma, researchers need seamless access to data, and they must adopt a more data-driven approach to their work. This transformation isn’t just about wrangling data or building new tools. It requires biopharmas to embrace digitalization fully, involving people, culture, platforms, and, of course, data, across every aspect of the organization.
By partnering with TXI to address data fragmentation and silos that hinder scientific breakthroughs, biopharmas can accelerate the development of novel treatments and ultimately bring them to patients faster and more efficiently.
